Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGM282 in primary sclerosing cholangitis
NL-OMON43892Phase 2Active, not recruiting
- Sponsor
- NGM Biopharmaceuticals
- Start
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of aldafermin in Primary Sclerosing Cholangitis (PSC) (3 arms), sponsored by NGM Biopharmaceuticals. Primary endpoint: Mean change in alkaline phosphatase. Started Jun 2016; status: active, not recruiting.
02
Drugs
aldafermin
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NL-OMON43892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43892.